ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0646

Dark Adaptometry Screening for Hydroxychloroquine Retinopathy: A Pilot Study

Robert Yood1, Elinor Mody1, Bradley Daines1, Kathryn Deliso2, Eugenio Candal1, Ahmed Ramram1, Stephen Brimer3, Alondra Msallem2 and Larry Baitch2, 1Reliant Medical Group, Worcester, MA, 2MCPHS University, Worcester, MA, 3Saint Vincent Hospital, Worcester, MA

Meeting: ACR Convergence 2021

Keywords: Disease-Modifying Antirheumatic Drugs (Dmards), Drug toxicity

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 7, 2021

Title: Measures & Measurement of Healthcare Quality Poster (0623–0659)

Session Type: Poster Session B

Session Time: 8:30AM-10:30AM

Background/Purpose: Hydroxychloroquine (HCQ) is widely used in the treatment of rheumatic diseases. The use of HCQ is complicated by HCQ-induced retinopathy, which may lead to irreversible visual loss. Current guidelines recommend annual screening for ocular damage with optical coherence tomography (OCT) and visual field (VF) testing beginning after 5 years of treatment with HCQ.

Dark Adaptometry (DA) tests the ability of the retina to recover its sensitivity after exposure to a bright, calibrated flash of light. This test shows high sensitivity and specificity as a biomarker for macular degeneration, a disease of the central retina. We hypothesized that DA might be more sensitive to retinal changes consequent to HCQ treatment than currently recommended tests and thus be useful as a novel screening test for HCQ retinopathy. We performed a pilot study to establish this test’s diagnostic potential.

Methods: Patients aged 20-70 were eligible for participation if they had documentation of current treatment with HCQ and at least one prescription annually for the preceding 3 or more years. Exclusion criteria included diabetes mellitus, treatment with tamoxifen, active ocular disease and patients with high myopia. Patients were also excluded if they had not had an eye examination, including VF or OCT within the prior 18 months.

DA was performed using the Rapid Test protocol on all patients. In this protocol, patient subjects who did not reach a criterion level of sensitivity prior to 6.5 minutes were deemed to have failed the test.

Results: Thirty patients aged were recruited from a large multispecialty group practice and an academic optometry clinic. HCQ daily dosages at the time of the DA study ranged from 1.8 to 6.8 mg/kg with a median of 4.0 mg/kg. Cumulative dosages ranged from 420g to 4700g. with a median of 930g. The median number of years since HCQ was first prescribed was 9. No subjects had symptoms of HCQ retinopathy or positive indications of retinopathy in OCT imaging or VF testing.

Fifty-four eyes were successfully tested in 26 of the 30 study subjects. Of the eyes tested, 36 (67%) passed and 18 (33%) failed the DA test. Of the subjects tested, 40% showed at least one abnormal DA time. Of those eyes passing the test, 5 eyes (9% of the cohort) showed a “late normal” DA time between 6.0 and 6.4 minutes. There was no significant correlation with DA time for daily dosage, cumulative dosage, patient age or duration of HCQ treatment.

Conclusion: The high number of subjects with abnormal DA times was quite unexpected, given the absence of visual symptomology or objective abnormalities on OCT and VF testing. These results suggest that DA may provide a more sensitive biomarker for ocular changes due to HCQ than conventional OCT and VF testing. However, we do not know how specific this test is for retinopathy, i.e., whether those abnormal delays will precede changes on ocular coherence tomography, visual fields, or the onset of visual disturbances in patients with continued exposure to HCQ. This pilot study therefore warrants a larger cohort, longitudinal study to establish the specificity of dark adaptometry prior to its acceptance as a screening test to improve the safety of treatment with HCQ.


Disclosures: R. Yood, None; E. Mody, None; B. Daines, None; K. Deliso, None; E. Candal, None; A. Ramram, None; S. Brimer, None; A. Msallem, None; L. Baitch, Maculogix Inc, 6.

To cite this abstract in AMA style:

Yood R, Mody E, Daines B, Deliso K, Candal E, Ramram A, Brimer S, Msallem A, Baitch L. Dark Adaptometry Screening for Hydroxychloroquine Retinopathy: A Pilot Study [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/dark-adaptometry-screening-for-hydroxychloroquine-retinopathy-a-pilot-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/dark-adaptometry-screening-for-hydroxychloroquine-retinopathy-a-pilot-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology